top of page
Evidence-First-Education-logo

Oxytocin in 2026: What the "Love Hormone" Hype Got Wrong — and What Research Actually Supports

The Peptides Place Editorial Team
Oct 12
8 min read

Bottom line


Oxytocin earned its "love hormone" nickname honestly — it is a real peptide hormone central to childbirth, breastfeeding, and social bonding. But the popular claims went much further than the evidence: that a nasal spray could make you more trusting, more sociable, or treat autism. The largest clinical trial, published in the New England Journal of Medicine in 2021, found no benefit for autism, and years of follow-up studies produced mixed or negative results. That is not the end of the story, though. In 2026, oxytocin research is having a more rigorous second act: a large preregistered study narrowed down exactly when oxytocin affects trust, and new clinical trials are testing it for migraine, PTSD, IVF implantation, and bone health — with sharper questions and better designs than the hype era. None of these uses is an approved treatment, and oxytocin nasal sprays sold online are not backed by the evidence their marketing implies.


What oxytocin actually is


Oxytocin is a nonapeptide — a chain of nine amino acids — produced in the hypothalamus and released by the posterior pituitary gland. Its established medical roles are in reproduction: stimulating uterine contractions during labor and triggering milk let-down during breastfeeding. That is also the basis of its only FDA-approved form: an injection used in hospitals during labor, delivery, and the postpartum period. There is no FDA-approved oxytocin nasal spray, pill, or supplement.



Because oxytocin also acts in the brain, researchers spent two decades asking whether it could be repurposed for social and psychiatric conditions. That question is legitimate. The answers turned out to be far narrower than the headlines suggested.


Where the "love hormone" hype came from


In 2005, a study led by Michael Kosfeld at the University of Zurich reported that participants who received oxytocin via nasal spray entrusted more money to a stranger in an economic "trust game" than participants who received a placebo. The effect disappeared when the human partner was replaced by a computer, suggesting the effect was social rather than a general willingness to take risks. Published in Nature, the finding launched a thousand headlines about a "trust hormone" in a bottle.



The problem: follow-up studies were inconsistent. Some replicated the effect; many did not. Critics pointed to small samples, varying methods, and hypotheses formed after seeing the data. Within a decade, the field itself acknowledged the skepticism — the authors of a 2026 paper in the Proceedings of the National Academy of Sciences opened by noting that "low power, HARKing (hypothesizing after the results are known), and replication failures have clouded the field."



What the big trials actually found


The clearest reality check came from autism research. Small early studies had hinted that intranasal oxytocin might improve social functioning in autistic children, and some clinicians were already prescribing it off-label. To settle the question, a large multisite U.S. trial led by Linmarie Sikich at Duke University enrolled 290 children and adolescents with autism, ages 3 to 17, and randomized them to daily intranasal oxytocin or placebo for 24 weeks. The primary outcome was a standardized measure of social withdrawal.


The result: no significant difference between the oxytocin and placebo groups. Parents in both groups reported improvements — but the improvements were the same with or without the drug. As Sikich put it, the benefits parents thought they were seeing were "probably not related to the oxytocin." The findings were published in the New England Journal of Medicine in October 2021.



That trial did not prove oxytocin does nothing in any context. It showed that daily intranasal oxytocin, as tested, does not improve social functioning in autistic children generally. That distinction matters — and it is the distinction the second act of oxytocin research is built on.


The 2026 second act: sharper questions, better trials


Trust — but only for the already distrustful


In August 2026, an international team led by Ernst Fehr (University of Zurich) published the most careful test yet of oxytocin and trust. They recruited 359 men who scored low on dispositional trust, randomly assigned them to oxytocin or placebo nasal spray, and had them play an anonymous trust game. The oxytocin group entrusted roughly 15% more money to their partners. Pooling the data with an earlier comparable sample (578 men total), the increase was 16.9% — and the study was preregistered with its hypothesis stated in advance, addressing the methodological criticisms that had dogged the field.


Limitations are explicit and important. The study enrolled men only (deliberately, to match earlier work — so nothing here generalizes to women). It measured money moved in a lab game, not real-world trust. And the biological mechanism remains unknown: the experiment measured decisions, not brain activity. What it does establish is that oxytocin's trust effect is real but selective and conditional — not a general "trust spray."



Migraine — through a completely different mechanism


In March 2026, Tonix Pharmaceuticals announced that the first participant had been dosed in a Phase 1 investigator-initiated study of TNX-1900, its intranasal oxytocin formulation, for migraine and craniofacial pain. The study, run at Erasmus University Medical Center under Professor Antoinette Maassen van den Brink, is testing the drug in healthy female volunteers using a trigeminal nerve reactivity model — measuring forehead blood-flow responses to capsaicin and electrical stimulation.


The rationale comes from animal research: intranasal oxytocin appears to bind oxytocin receptors in the trigeminal ganglion, blocking the release of CGRP — the same neuropeptide targeted by the current generation of migraine drugs, but through a different mechanism (blocking release rather than blocking the receptor). This is a Phase 1 pharmacodynamic study, meaning it is testing biological effects in a model system, not whether the drug relieves migraines in patients. No results have been published yet.


IVF — by blocking oxytocin, not adding it


Here is the twist the hype never predicted. In July 2026, the Swiss company ReproNovo dosed the first participant in NORDIC, a European Phase 2 trial of RPN-002 (nolasiban) — an oral drug that blocks the oxytocin receptor rather than activating it. The trial, registered as EU CT 2025-524896-22, is a randomized, double-blind, placebo-controlled study in about 120 women across five European sites undergoing IVF or ICSI.


The logic: uterine contractions around the time of embryo transfer are associated with lower implantation rates, and oxytocin drives uterine contractions. An oxytocin blocker taken around transfer could quiet the uterus during the critical implantation window. This is the opposite of the "more oxytocin is better" story — a reminder that the hormone's effects depend entirely on context, dose, and tissue.



PTSD, caregiver stress, and bone health — trials now recruiting


Several Phase 2 trials are currently testing intranasal oxytocin in new contexts:


  • PTSD (NCT06194851): The VA Office of Research and Development is testing intranasal oxytocin as an add-on to brief couples therapy for veterans with PTSD — 240 participants, randomized against placebo, measuring PTSD symptoms and relationship satisfaction. (Note: trial trackers disagree on whether this study is currently recruiting; check the ClinicalTrials.gov entry directly for current status.)

  • Caregiver stress (NCT06364228): The University of Nebraska is testing low- and high-dose intranasal oxytocin versus placebo over 21 days in female dementia caregivers, with brain imaging to see how the brain responds.


  • Bone health in autistic children (NCT05754073): A Department of Defense-funded Phase 2 study at Massachusetts General Hospital and the University of Virginia is testing whether intranasal oxytocin improves bone density in children with autism ages 6 to 18 — based on evidence that oxytocin promotes bone formation, not on the discredited social-function claims.



All of these are early-stage. Phase 2 trials test whether something might work and whether it is safe — they do not establish treatments.


The gray-market problem


While researchers run careful trials, online sellers have already decided what oxytocin does. Nasal sprays marketed for "emotional bonding," "intimacy," stress relief, and "overall health and longevity" are sold directly to consumers — one vendor offers 25 IU per spray with claims spanning bonding, blood pressure, metabolic control, and cortisol regulation.



Contrast that with what even a compounding pharmacy selling prescription oxytocin spray says on its own page: "Compounded intranasal and sublingual oxytocin is not FDA-approved," and the evidence for marketed claims about bonding, intimacy, mood, or social behavior "is investigational and not established." The same page notes that how much oxytocin reaches the brain after nasal dosing "is still being studied and is not established."



That is the honest state of the science in one paragraph, from a seller. The research-grade questions — who it helps, at what dose, through what mechanism — are still open. A bottle with a dropper is not the answer to them.


What we still don't know


  • Brain delivery is debated. Whether intranasal oxytocin meaningfully reaches the brain, and how much, remains an open question — some researchers argue nasal delivery reaches the brain via olfactory and trigeminal pathways, while others note it has not been conclusively established.

  • Sex differences are understudied. The landmark 2026 trust study enrolled men only. Oxytocin biology differs by sex, and most findings cannot be assumed to generalize.

  • Dosing is unsettled. Animal research has shown an "inverted U" dose-response — re is not always better, and high doses can inhibit the effects seen at lower ones.

  • Small samples persist. Outside the 2026 trust study and the 2021 autism trial, most human oxytocin studies remain small, and small studies produce noisy results.


FAQ


Is oxytocin FDA-approved as a nasal spray?


No. The only FDA-approved oxytocin product is an injection used in hospitals for labor, delivery, and postpartum care. Nasal sprays, troches, and other compounded forms are off-label and not FDA-approved.


Can I buy oxytocin spray online?


Products marketed as oxytocin nasal sprays are sold online, but they are unregulated, their contents and dosing are unverified, and the benefits claimed for them are not established by clinical evidence. This article is educational, not a recommendation.


Does oxytocin make you more trusting?


The best current evidence says: slightly, and only in specific circumstances. A large 2026 preregistered study found about a 15% increase in trusting behavior in a lab money game — but only in men who already scored low on trust, and the mechanism is unknown. That is a long way from a "trust spray."


Is there an oral form of oxytocin?

Oxytocin itself is a peptide and would be digested if swallowed, which is why research uses nasal delivery or injections. The oral drug in development that targets the oxytocin system — nolasiban — is a receptor blocker for IVF, not an oxytocin supplement. For more on why oral peptides are hard, see our explainer: https://www.thepeptidesplace.com/post/oral-peptides-why-no-more-injections-isn-t-as-simple-as-it-sounds


This article is for educational purposes only and is not medical advice. Oxytocin products discussed here are investigational for the conditions described; talk to a qualified clinician about any health decisions.


Sources


  • Vogt B, Bengart P, Declerck C, Fehr E. "Oxytocin increases trust in men low in dispositional trust." Proceedings of the National Academy of Sciences. 2026;123(32):e2602655123. DOI: 10.1073/pnas.2602655123.

  • Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. "Oxytocin increases trust in humans." Nature. 2005;435:673-676. PMID 15931222.

  • Sikich L et al. Intranasal oxytocin for autism spectrum disorder. New England Journal of Medicine. October 2021. (290 children enrolled, 24-week randomized placebo-controlled trial; no significant between-group difference in social functioning.)

  • Tonix Pharmaceuticals press release, March 26, 2026: first participant dosed in Phase 1 investigator-initiated study of TNX-1900 (intranasal potentiated oxytocin) for migraine/craniofacial pain, Erasmus University Medical Center.

  • ReproNovo announcement via MedPath, July 6, 2026: first participant dosed in EU Phase 2 NORDIC trial of RPN-002 (nolasiban), oral oxytocin receptor antagonist for embryo Bottom line

  • ClinicalTrials.gov NCT05754073: Phase 2 study of intranasal oxytocin for bone health in children with autism spectrum disorder (Massachusetts General Hospital / University of Virginia).

  • ClinicalTrials.gov NCT06194851: Phase 2 study of intranasal oxytocin augmentation of brief couples therapy for veterans with PTSD (VA Office of Research and Development).

  • ClinicalTrials.gov NCT06364228: intranasal oxytocin intervention for caregivers of persons with dementia (University of Nebraska).

 
 
 

Recent Posts

See All

Comments

Button
bottom of page